An official website of the United States government
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Trial Status: active
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to
detect regional nodal metastases.
Inclusion Criteria
At least 18 years of age.
Signed informed consent.
Untreated, histologically confirmed adenocarcinoma of the prostate.
High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA >20 ng/mL).
Patients electing to undergo RP with PLND.
Exclusion Criteria
Administration of any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
Patients with known predominant small cell or neuroendocrine PC.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06056830.
Locations matching your search criteria
United States
Alabama
Birmingham
University of Alabama at Birmingham Cancer Center
Status: Active
Name Not Available
Arizona
Scottsdale
Mayo Clinic in Arizona
Status: Active
Name Not Available
California
Orange
UC Irvine Health/Chao Family Comprehensive Cancer Center
